53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

9 trials found

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05124925 (ClinicalTrials.gov)	January 26, 2022	8/11/2021	Biopsy Study in Patients With Sjogren's Disease to Investigate Safety and Effect of Ianalumabon Sali ...	An Open-label, Non-randomized, Biopsy-based Mechanistic Study on Efficacy, Pharmacokinetics, Pharmac ...	Sjogren Syndrome	Biological: Ianalumab	Novartis Pharmaceuticals	NULL	Not yet recruiting	18 Years	N/A	All	24	Phase 2	NULL
2	EUCTR2016-003292-22-IT (EUCTR)	20/11/2017	25/05/2021	Study of safety and efficacy of ianalumab in patients with primary Sjogren's Syndrome (pSS).	A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the ...	Primary Sjogren's syndrome. MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogre ...	Product Name: ianalumab Product Code: [VAY736] INN or Proposed INN: IANALUMAB	NOVARTIS PHARMA AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	Portugal;United States;Taiwan;Spain;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;Fra ...
3	EUCTR2016-003292-22-PL (EUCTR)	28/09/2017	23/08/2017	Study of safety and efficacy of ianalumab in patients with primarySjogren's Syndrome (pSS)	A randomized, double-blind, placebo-controlled multicenter phase 2 doseranging study to assess the s ...	Primary Sjogren’s syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	United States;Portugal;Taiwan;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;Fra ...
4	EUCTR2016-003292-22-NL (EUCTR)	25/07/2017	19/04/2017	Study of safety and efficacy of ianalumab in patients with primarySjogren's Syndrome (pSS)	A randomized, double-blind, placebo-controlled multicenter phase 2 doserangingstudy to assess the sa ...	Primary Sjogren’s syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	Portugal;United States;Taiwan;Spain;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;Fra ...
5	EUCTR2016-003292-22-BE (EUCTR)	17/07/2017	26/04/2017	Study of safety and efficacy of ianalumab in patients with primary Sjogren's Syndrome (pSS)	A randomized, double-blind, placebo-controlled multicenter phase 2 doseranging study to assess the s ...	Primary Sjogren’s syndrome MedDRA version: 20.0;Level: PT;Classification code 10040767;Term: Sjogren ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	United States;Portugal;Taiwan;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;Fra ...
6	EUCTR2016-003292-22-AT (EUCTR)	19/06/2017	17/05/2017	A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the ...	A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the ...	Primary Sjogren’s syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	United States;Portugal;Taiwan;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;Fra ...
7	EUCTR2016-003292-22-DE (EUCTR)	06/06/2017	06/03/2017	Study of safety and efficacy of ianalumab in patients with primary Sjogren’s Syndrome (pSS)	A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the ...	Primary Sjogren’s syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	Portugal;United States;Taiwan;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;Fra ...
8	EUCTR2016-003292-22-PT (EUCTR)	05/06/2017	20/03/2017	Study of safety and efficacy of ianalumab in patients with primary Sjogren’s Syndrome (pSS)	A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the ...	Primary Sjogren’s syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	Portugal;United States;Taiwan;Spain;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;Fra ...
9	EUCTR2016-003292-22-GB (EUCTR)	26/05/2017	20/03/2017	Study of safety and efficacy of ianalumab in patients with primary Sjogren’s Syndrome (pSS)	A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the ...	Primary Sjogren’s syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 2	United States;Portugal;Taiwan;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;Fra ...

First Previous1Next Last